卡提素辅助治疗耐多药结核病的疗效观察

Observation of therapeuric effect of BCG in adjunctive treatment of MDR-TB

目的评价卡提素辅助治疗耐多药结核病(MDR-TB)的疗效。方法104例MDR-TB患者随机分为两组,两组病人的化疗方案均采用3DAOZT/9DTO,治疗组在化疗强化期加用卡提素辅助治疗。结果治疗3个月和疗程结束时治疗组痰菌阴转率为53.9%和78.2%,对照组为15.4%和47.1%,有显著的统计学差异(P<0.01和P<0.05),治疗组疗效强于对照组。结论卡提素是辅助治疗耐多药结核病较为有效的药物。

Objective To evaluate the therapeutic effects of bacillus calmette guerin （BCG） in the adjunctive treatment of multidrug resistance tuberculosis （ MDR-TB ）. Methods A randomized control trial was conducted and 104 MDR-TB patients were randomly distributed into two groups. The patients in the two groups were treated by the same chemotherapeutic regimen of 3DAOZT/9DTO, but the trial group was additionally treated with BCG as an adjunctive treatment in the therapy-enhancement phase. Results The sputum conversion rate of positive-turned - negative were, respectively, at the end of 3rd month and of the treatment course, 53.9% and 78.2% for the trial group, and 15.4% and 47.1% for the control group. Both the comparisons between the two groups reached significant levels of P 〈 0. 01 and P 〈 0. 05. Conclusion BCG is an effective drug in the adjunctive treatment of MDR-TB.